Advances in magnetic resonance (2009)

Investigative Radiology

Volumn 44, Issue 12, 2009, Pages 808-812

  Runge, Val M ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Contrast media; Gadolinium; Magnetic resonance

Indexed keywords

GADOLINIUM;

CLINICAL PRACTICE; CONTRAST ENHANCEMENT; HUMAN; IMAGING SYSTEM; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 73349117522     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181c2984e     Document Type: Review

References (126)

1. Anzalone N, Scomazzoni F, Cirillo M, et al. Follow-up of coiled cerebral aneurysms: comparison of three-dimensional time-of-flight magnetic resonance angiography at 3 tesla with three-dimensional time-of-flight magnetic resonance angiography and contrast-enhanced magnetic resonance angiog-raphy at 1.5 Tesla. Invest Radiol. 2008;43:559-567.
2. Attenberger UI, Ingrisch M, Dietrich O, et al. Time-resolved 3D pulmonary perfusion MRI: comparison of different k-space acquisition strategies at 1.5 and 3 T. Invest Radiol. 2009;44:525-531.
3. Attenberger UI, Runge VM, Jackson CB, et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol. 2009;44:251-256.
4. Attenberger UI, Runge VM, Stemmer A, et al. Diffusion weighted imaging: a comprehensive evaluation of a fast spin echo DWI sequence with BLADE (PROPELLER) k-space sampling at 3 T, using a 32-channel head coil in acute brain ischemia. Invest Radiol. 2009;44:656-661.
5. Attenberger UI, Runge VM, Williams KD, et al. T1-weighted brain imaging with a 32-channel coil at 3T using TurboFLASH BLADE compared with standard cartesian k-space sampling. Invest Radiol. 2009;44:177-183.
6. Bolbos RI, Ma CB, Link TM, et al. In vivo T1rho quantitative assessment of knee cartilage after anterior cruciate ligament injury using 3 Tesla magnetic resonance imaging. Invest Radiol. 2008;43:782-788.
7. Bueltmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla. Invest Radiol. 2008;43:695-702.
8. Bunck AC, Engelen MA, Schnackenburg B, et al. Feasibility of functional cardiac MR imaging in mice using a clinical 3 Tesla whole body scanner. Invest Radiol. 2009;44:749-756.
9. Chagla GH, Busse RF, Sydnor R, et al. Three-dimensional fluid attenuated inversion recovery imaging with isotropic resolution and nonselective adi-abatic inversion provides improved three-dimensional visualization and cerebrospinal fluid suppression compared to two-dimensional flair at 3 tesla. Invest Radiol. 2008;43:547-551.
10. Edelman RR, Dunkle E, Koktzoglou I, et al. Rapid whole-brain magnetic resonance imaging with isotropic resolution at 3 Tesla. Invest Radiol. 2009;44:54-59.
11. Fries P, Runge VM, Bucker A, et al. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model. Invest Radiol. 2009;44:200-206.
12. Fries P, Runge VM, Kirchin MA, et al. Diffusion-weighted imaging in patients with acute brain ischemia at 3 T: current possibilities and future perspectives comparing conventional echoplanar diffusion-weighted imaging and fast spin echo diffusion-weighted imaging sequences using BLADE (PROPELLER). Invest Radiol. 2009;44:351-359.
13. Ganguli S, Pedrosa I, Smith MP, et al. Low dose pedal magnetic resonance angiography at 3 tesla with time-resolved imaging of contrast kinetics: a feasibility study. Invest Radiol. 2008;43:650-655.
14. Gloviczki ML, Glockner J, Gomez SI, et al. Comparison of 1.5 and 3 T BOLD MR to study oxygenation of kidney cortex and medulla in human renovascular disease. Invest Radiol. 2009;44:566-571.
15. Hambrock T, Futterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol. 2008;43:686-694.
16. Jeukens CR, Vlooswijk MC, Majoie HJ, et al. Hippocampal MRI volumetry at 3 Tesla: reliability and practical guidance. Invest Radiol. 2009;44:509-517.
17. Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacoki-netic models in the discrimination of malignant from normal tissue. Invest Radiol. 2009;44:577-584.
18. Maroules CD, McColl R, Khera A, et al. Assessment and reproducibility of aortic atherosclerosis magnetic resonance imaging: impact of 3-Tesla field strength and parallel imaging. Invest Radiol. 2008;43:656-662.
19. Michaely HJ, Attenberger UI, Dietrich O, et al. Feasibility of gadofosveset-enhanced steady-state magnetic resonance angiography of the peripheral vessels at 3 Tesla with Dixon fat saturation. Invest Radiol. 2008;43:635-641.
20. Mori N, Miki Y, Kasahara S, et al. Susceptibility-Weighted Imaging at 3 Tesla Delineates the Optic Radiation. Invest Radiol. 2009;44:140-145.
21. Mori N, Miki Y, Kikuta K, et al. Microbleeds in moyamoya disease: susceptibility-weighted imaging versus T2*-weighted imaging at 3 Tesla. Invest Radiol. 2008;43:574-579.
22. Notohamiprodjo M, Horng A, Pietschmann MF, et al. MRI of the knee at 3T: first clinical results with an isotropic PDfs-weighted 3D-TSE-sequence. Invest Radiol. 2009;44:585-597.
23. Park BK, Lee HM, Kim CK, et al. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol. 2008;43:789-793.
24. Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol. 2009;44:553-558.
25. Prompona M, Cyran C, Nikolaou K, et al. Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset. Invest Radiol. 2009;44:369-374.
26. Stanwell P, Russell P, Carter J, et al. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Invest Radiol. 2008;43: 745-751.
27. Tallantyre EC, Morgan PS, Dixon JE, et al. A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Invest Radiol. 2009;44:491-494.
28. Trattnig S, Burstein D, Szomolanyi P, et al. T1(Gd) gives comparable information as Delta T1 relaxation rate in dGEMRIC evaluation of cartilage repair tissue. Invest Radiol. 2009;44:598-602.
29. Utting JF, Kozerke S, Luechinger R, et al. Feasibility of k-t BLAST for BOLD fMRI with a spin-echo based acquisition at 3 T and 7 T. Invest Radiol. 2009;44:495-502.
30. Yoon MA, Kim SH, Park HS, et al. Value of dual contrast liver MRI at 3.0 T in differentiating well-differentiated hepatocellular carcinomas from dys-plastic nodules: preliminary results of multivariate analysis. Invest Radiol. 2009;44:641-649.
31. Yrjana SK, Vaara T, Karttunen A, et al. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol. 2008;43:267-275.
32. Kwee TC, Quarles van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44: 683-690.
33. Heverhagen JT, Bourekas E, Sammet S, et al. Time-of-flight magnetic resonance angiography at 7 Tesla. Invest Radiol. 2008;43:568-573.
34. Kraff O, Bitz AK, Kruszona S, et al. An eight-channel phased array RF coil for spine MR imaging at 7 Tesla. Invest Radiol. 2009;44:734-740.
35. Kraff O, Theysohn JM, Maderwald S, et al. High-resolution MRI of the human parotid gland and duct at 7 Tesla. Invest Radiol. 2009;44:518-524.
36. Krug R, Stehling C, Kelley DA, et al. Imaging of the musculoskeletal system in vivo using ultra-high field magnetic resonance at 7 T. Invest Radiol. 2009;44:613-618.
37. Amano Y, Takahama K, Kumita S. Noncontrast-enhanced three-dimensional magnetic resonance aortography of the thorax at 3.0 T using respiratory- compensated T1-weighted k-space segmented gradient-echo imaging with radial data sampling: preliminary study. Invest Radiol. 2009;44:548-552.
38. Anzidei M, Napoli A, Marincola BC, et al. High-resolution steady state MR angiography of the carotid arteries: are intravascular agents necessary? Feasibility and preliminary experience with gadobenate dimeglumine. Invest Radiol. 2009;44:784-792.
39. Berg F, Bangard C, Bovenschulte H, et al. Feasibility of peripheral contrast-enhanced magnetic resonance angiography at 3.0 Tesla with a hybrid technique: comparison with digital subtraction angiography. Invest Radiol. 2008;43:642-649.
40. Huppertz A, Kroll H, Klessen C, et al. Biphasic blood pool contrast agent-enhanced whole-body MR angiography for treatment planning in patients with significant arterial stenosis. Invest Radiol. 2009;44:422-432.
41. Jerosch-Herold M, Vazquez G, Wang L, et al. Variability of myocardial blood flow measurements by magnetic resonance imaging in the multiethnic study of atherosclerosis. Invest Radiol. 2008;43:155-161.
42. Katoh M, Spuentrup E, Stuber M, et al. Flow targeted 3D Steady-State Free-Precession (SSFP) coronary MR angiography: comparison of three different imaging approaches. Invest Radiol. 2009;44:757-762.
43. Kos S, Huegli R, Hofmann E, et al. Feasibility of real-time magnetic resonance-guided angioplasty and stenting of renal arteries in vitro and in Swine, using a new polyetheretherketone-based magnetic resonance-compatible guidewire. Invest Radiol. 2009;44:234-241.
44. Kramer H, Zenge M, Schmitt P, et al. Peripheral magnetic resonance angiog-raphy (MRA) with continuous table movement at 3.0 T: initial experience compared with step-by-step MRA. Invest Radiol. 2008;43:627-634.
45. Kramer NA, Kruger S, Schmitz S, et al. Preclinical evaluation of a novel fiber compound MR guidewire in vivo. Invest Radiol. 2009;44:390-397.
46. Krishnam MS, Tomasian A, Deshpande V, et al. Noncontrast 3D steady-state free-precession magnetic resonance angiography of the whole chest using nonselective radiofrequency excitation over a large field of view: comparison with single-phase 3D contrast-enhanced magnetic resonance angiography. Invest Radiol. 2008;43:411-420. (Pubitemid 351769899)
47. Krishnam MS, Tomasian A, Malik S, et al. Three-dimensional imaging of pulmonary veins by a novel steady-state free-precession magnetic resonance angiography technique without the use of intravenous contrast agent: initial experience. Invest Radiol. 2009;44:447-453.
48. Krombach GA, Wehner M, Perez-Bouza A, et al. Magnetic resonance-guided angioplasty with delivery of contrast-media doped solutions to the vessel wall: an experimental study in swine. Invest Radiol. 2008;43:530-537.
49. Ley S, Unterhinninghofen R, Ley-Zaporozhan J, et al. Validation of magnetic resonance phase-contrast flow measurements in the main pulmonary artery and aorta using perivascular ultrasound in a large animal model. Invest Radiol. 2008;43:421-426.
50. Ley-Zaporozhan J, Kreitner KF, Unterhinninghofen R, et al. Assessment of thoracic aortic dimensions in an experimental setting: comparison of different unenhanced magnetic resonance angiography techniques with electrocardiogram- gated computed tomography angiography for possible application in the pediatric population. Invest Radiol. 2008;43:179-186.
51. Liu X, Bi X, Huang J, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0 T: comparison with steady-state free precession technique at 1. 5 T. Invest Radiol. 2008;43:663-668.
52. Lohan DG, Tomasian A, Saleh RS, et al. Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. Invest Radiol. 2009;44:207-217.
53. Ludemann L, Nafz B, Elsner F, et al. Absolute quantification of regional renal blood flow in swine by dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent. Invest Radiol. 2009;44:125-134.
54. Peldschus K, Hamdorf M, Robert P, et al. Contrast-enhanced magnetic resonance angiography: evaluation of the high relaxivity low diffusible gadolinium-based contrast agent P846 in comparison with gadoterate me-glumine in rabbits at 1. 5 Tesla and 3.0 Tesla.Invest Radiol. 2008;43:837-842.
55. Rossi C, Boss A, Artunc F, et al. Comprehensive assessment of renal function and vessel morphology in potential living kidney donors: an MRI-based approach. Invest Radiol. 2009;44:705-711.
56. Tilak GS, Hsu LY, Hoyt RF Jr, et al. In vivo T2-weighted magnetic resonance imaging can accurately determine the ischemic area at risk for 2-day-old nonreperfused myocardial infarction. Invest Radiol. 2008;43:7-15.
57. Tomasian A, Krishnam MS, Lohan DG, et al. Adult Tetralogy of Fallot: quantitative assessment of pulmonary perfusion with time-resolved three dimensional magnetic resonance angiography. Invest Radiol. 2009;44:31-37.
58. Tomasian A, Lohan DG, Laub G, et al. Noncontrast 3D steady state free precession magnetic resonance angiography of the thoracic central veins using nonselective radiofrequency excitation over a large field of view: initial experience. Invest Radiol. 2008;43:306-313.
59. Voth M, Haneder S, Huck K, et al. Peripheral magnetic resonance angiog-raphy with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T. Invest Radiol. 2009;44:627-633.
60. Weckbach S, Findeisen HM, Schoenberg SO, et al. Systemic cardiovascular complications in patients with long-standing diabetes mellitus: comprehensive assessment with whole-body magnetic resonance imaging/magnetic resonance angiography. Invest Radiol. 2009;44:242-250.
61. Zhang Z, Fan Z, Carroll TJ, et al. Three-dimensional T2-weighted MRI of the human femoral arterial vessel wall at 3.0 Tesla. Invest Radiol. 2009;44: 619-626.
62. Bannier E, Neyran B, Cieslar K, et al. Free breathing hyperpolarized 3He lung ventilation spiral MR imaging. Invest Radiol. 2009;44:185-191.
63. Baumann T, Ludwig U, Pache G, et al. Detection of pulmonary nodules with move-during-scan magnetic resonance imaging using a free-breathing turbo inversion recovery magnitude sequence. Invest Radiol. 2008;43:359-367.
64. Boss A, Schaefer S, Martirosian P, et al. Magnetic resonance imaging of lung tissue: influence of body positioning, breathing and oxygen inhalation on signal decay using multi-echo gradient-echo sequences. Invest Radiol. 2008;43:433-438.
65. Elgeti T, Rump J, Hamhaber U, et al. Cardiac magnetic resonance elastog-raphy. Initial results. Invest Radiol. 2008;43:762-772.
66. Gast KK, Hawig K, Windirsch M, et al. Intrapulmonary 3He gas distribution depending on bolus size and temporal bolus placement. Invest Radiol. 2008;43:439-446.
67. Hung J, Francois C, Nelson NA, et al. Cardiac image modeling tool for quantitative analysis of global and regional cardiac wall motion. Invest Radiol. 2009;44:271-278.
68. Jang YM, Oh YM, Seo JB, et al. Quantitatively assessed dynamic contrast-enhanced magnetic resonance imaging in patients with chronic obstructive pulmonary disease: correlation of perfusion parameters with pulmonary function test and quantitative computed tomography. Invest Radiol. 2008; 43:403-410.
69. Kirschbaum SW, Baks T, Gronenschild EH, et al. Addition of the long-axis information to short-axis contours reduces interstudy variability of left-ventricular analysis in cardiac magnetic resonance studies. Invest Radiol. 2008;43:1-6.
70. Molinari F, Puderbach M, Eichinger M, et al. Oxygen-enhanced magnetic resonance imaging: influence of different gas delivery methods on the T1-changes of the lungs. Invest Radiol. 2008;43:427-432.
71. Montella S, Santamaria F, Salvatore M, et al. Assessment of chest high-field magnetic resonance imaging in children and young adults with noncystic fibrosis chronic lung disease: comparison to high-resolution computed tomography and correlation with pulmonary function. Invest Radiol. 2009; 44:532-538.
72. Roes SD, Hammer S, van der Geest RJ, et al. Flow assessment through four heart valves simultaneously using 3-dimensional 3-directional velocity-encoded magnetic resonance imaging with retrospective valve tracking in healthy volunteers and patients with valvular regurgitation. Invest Radiol. 2009;44:669-675.
73. Viard R, Tourneux P, Storme L, et al. Magnetic resonance imaging spatial and time study of lung water content in newborn lamb: methods and preliminary results. Invest Radiol. 2008;43:470-480.
74. Chiang WW, Takoudis CG, Lee SH, et al. Relationship between ventricular morphology and aqueductal cerebrospinal fluid flow in healthy and communicating hydrocephalus. Invest Radiol. 2009;44:192-199.
75. Christoforidis GA, Yang M, Kontzialis MS, et al. High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide. Invest Radiol. 2009;44:375-383.
76. Slotboom J, Schaer R, Ozdoba C, et al. A novel method for analyzing DSCE-images with an application to tumor grading. Invest Radiol. 2008; 43:843-853.
77. Wintersperger BJ, Runge VM, Tweedle MF, et al. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol. 2009;44:89-94.
78. Wu S, Thornhill RE, Chen S, et al. Relative recirculation: a fast, model-free surrogate for the measurement of blood-brain barrier permeability and the prediction of hemorrhagic transformation in acute ischemic stroke. Invest Radiol. 2009;44:662-668.
79. Franiel T, Ludemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol. 2008;43:481-487.
80. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at3.0Tesla. Invest Radiol. 2009;44:572-576.
81. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dime-glumine. Invest Radiol. 2009;44:135-139.
82. Li LP, Ji L, Santos EA, et al. Effect of nitric oxide synthase inhibition on intrarenal oxygenation as evaluated by blood oxygenation level-dependent magnetic resonance imaging. Invest Radiol. 2009;44:67-73.
83. Michaely HJ, Sourbron SP, Buettner C, et al. Temporal constraints in renal perfusion imaging with a 2-compartment model. Invest Radiol. 2008;43: 120-128.
84. Notohamiprodjo M, Glaser C, Herrmann KA, et al. Diffusion tensor imaging of the kidney with parallel imaging: initial clinical experience. Invest Radiol. 2008;43:677-685.
85. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
86. Sadick M, Schock D, Kraenzlin B, et al. Morphologic and dynamic renal imaging with assessment of glomerular filtration rate in a pcy-mouse model using a clinical 3.0 Tesla scanner. Invest Radiol. 2009;44:469-475.
87. Sourbron SP, Michaely HJ, Reiser MF, et al. MRI-measurement of perfusion and glomerular filtration in the human kidney with a separable compartment model. Invest Radiol. 2008;43:40-48.
88. Alsaid H, De Souza G, Bourdillon MC, et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of ApoE\-/\ mice: a pilot study. Invest Radiol. 2009;44:151-158.
89. Amemiya S, Akahane M, Aoki S, et al. Dynamic contrast-enhanced perfusion MR imaging with SPIO: a pilot study. Invest Radiol. 2009;44:503-508.
90. Asbach P, Warmuth C, Stemmer A, et al. High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocyte-specific contrast medium. Invest Radiol. 2008;43:809-815.
91. Bauner KU, Reiser MF, Huber AM. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol. 2009;44:95-104.
92. Bernd H, De Kerviler E, Gaillard S, et al. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol. 2009;44:336-342.
93. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
94. Chouker A, Lizak M, Schimel D, et al. Comparison of Fenestra VC Contrast-enhanced computed tomography imaging with gadopentetate dimeglumine and ferucarbotran magnetic resonance imaging for the in vivo evaluation of murine liver damage after ischemia and reperfusion. Invest Radiol. 2008;43:77-91.
95. Comte A, Kastler B, Laborie L, et al. Using a contrast-enhanced imaging sequence at 3-minute delay in 3-T magnetic resonance imaging for acute infarct evaluation. Invest Radiol. 2008;43:669-675.
96. Cyran CC, Sennino B, Chaopathomkul B, et al. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature. Invest Radiol. 2008;43:298-305.
97. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
98. Frericks BB, Wacker F, Loddenkemper C, et al. Magnetic resonance imaging of experimental inflammatory bowel disease: quantitative and qualitative analyses with histopathologic correlation in a rat model using the ultrasmall iron oxide SHU 555 C. Invest Radiol. 2009;44:23-30.
99. Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and SAFETY of Gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol. 2009;44:776-783.
100. Hammerstingl R, Adam G, Ayuso JR, et al. Comparison of 1.0 M Gadobu-trol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions: Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial. Invest Radiol. 2009;44:168-176.
101. Jacquier A, Boussel L, Amabile N, et al. Multidetector computed tomography in reperfused acute myocardial infarction. Assessment of infarct size and no-reflow in comparison with cardiac magnetic resonance imaging. Invest Radiol. 2008;43:773-781.
102. Katoh M, Haage P, Wiethoff AJ, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150.
103. Kaufels N, Korn R, Wagner S, et al. Magnetic resonance imaging of liver metastases: experimental comparison of anionic and conventional super-paramagnetic iron oxide particles with a hepatobiliary contrast medium during dynamic and uptake phases. Invest Radiol. 2008;43:496-503.
104. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210.
105. Kim SH, Lee JM, Lee MW, et al. Diagnostic accuracy of 3.0-Tesla rectal magnetic resonance imaging in preoperative local staging of primary rectal cancer. Invest Radiol. 2008;43:587-593.
106. Lee DH, Kim SH, Lee JM, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Invest Radiol. 2009;44: 311-321.
107. Lijowski M, Caruthers S, Hu G, et al. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol. 2009;44:15-22.
108. Mewton N, Croisille P, Revel D, et al. Left ventricular postmyocardial infarction remodeling studied by combining MR-tagging with delayed MR contrast enhancement. Invest Radiol. 2008;43:219-228.
109. Peller M, Schwerdt A, Hossann M, et al. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Invest Radiol. 2008;43:877-892.
110. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
111. Radermacher KA, Beghein N, Boutry S, et al. In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multi-modal approach using MR imaging and EPR spectroscopy. Invest Radiol. 2009;44:398-404.
112. Sardanelli F, Fausto A, Esseridou A, et al. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol. 2008;43:236-242.
113. Schlossbauer T, Leinsinger G, Wismuller A, et al. Classification of small contrast enhancing breast lesions in dynamic magnetic resonance imaging using a combination of morphological criteria and dynamic analysis based on unsupervised vector-quantization. Invest Radiol. 2008;43: 56-64.
114. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
115. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
116. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific Gadolinium-based MR contrast agent EP-2104R: results of a phase ii clinical study of feasibility. Invest Radiol. 2009;44:697-704.
117. Walder N, Petter-Puchner AH, Brejnikow M, et al. Manganese enhanced magnetic resonance imaging in a contusion model of spinal cord injury in rats: correlation with motor function. Invest Radiol. 2008;43:277-283.
118. Wang H, Sun X, Chen F, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using mul-tiparametric magnetic resonance imaging in correlation with microangiog-raphy and histology. Invest Radiol. 2009;44:44-53.
119. Welsch GH, Mamisch TC, Hughes T, et al. In vivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilage. Invest Radiol. 2008;43:619-626.
120. Woods M, Caravan P, Geraldes CF, et al. The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol. 2008;43:861-870.
121. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. Invest Radiol. 2008;4:538-546.
122. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511.
123. Zech CJ, Herrmann KA, Dietrich O, et al. Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol. 2008;43:261-266.
124. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
125. Zheng J, Ochoa E, Misselwitz B, et al. Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Invest Radiol. 2008;43:49-55.
126. Zhu D, Lu X, Hardy PA, et al. Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors. Invest Radiol. 2008;43:129-140.